Novo Nordisk (NVO) Stock

Novo Nordisk Stock Details, Movements and Public Alerts

Stock Details

Novo Nordisk (NVO), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $79.92. Over the past 52 weeks, it has ranged between $57.00 and $145.26. This places the current price at 55.0% of its 52-week high and 40.2% above its 52-week low. Recent trading volume was recorded at 2,511,570. The 14-day Relative Strength Index (RSI) stands at 56.73, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $66.31 by 20.52%. Similarly, it is below its 200-day moving average of $93.79 by 14.79%. The MACD histogram is 0.60, indicating bullish momentum (MACD Line: 1.25, Signal Line: 0.64).

52-Week High

$145.26

52-Week Low

$57.00

Volume

2,511,570

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

20.20

Near market average

Forward P/E

18.02

Earnings expected to grow

PEG Ratio

1.31

Reasonably valued

Price to Book

15.23

EV/EBITDA

14.28

EPS (TTM)

$3.54

Price to Sales

1.01

Beta

0.21

Less volatile than market

Is NVO's P/E ratio considered high or low?
Novo Nordisk's current P/E ratio is 20.20, which is near the market average, suggesting the stock is fairly valued relative to its earnings.
How does NVO's Forward P/E compare to its current P/E?
Novo Nordisk's current P/E is 20.20 and its Forward P/E is 18.02. The lower Forward P/E suggests analysts expect earnings to grow in the coming year, potentially making the stock more attractively valued based on future earnings.
What does NVO's PEG ratio tell investors?
Novo Nordisk's PEG ratio is 1.31. A PEG ratio between 1.0 and 2.0 is generally considered to indicate fair value relative to expected growth.
How volatile is NVO compared to the overall market?
Novo Nordisk's beta value is 0.21. A beta below 1 indicates the stock is less volatile than the market. For example, if the market moves 10%, you might expect this stock to move less than 10%.

Performance & Growth

Profit Margin

34.50%

Operating Margin

49.70%

Return on Equity

88.10%

Return on Assets

23.30%

Revenue Growth (YoY)

19.50%

Earnings Growth (YoY)

15.00%

How profitable is NVO compared to its industry peers?
Novo Nordisk has a profit margin of 34.50%. This is a strong profit margin that's typically above average for most industries. It means the company is keeping $34.50 of profit from every $100 in sales. Profit margins vary by industry, and PHARMACEUTICAL PREPARATIONS companies typically need to be evaluated against their specific sector benchmarks.
What do NVO's ROE and ROA figures tell investors?
Novo Nordisk has a Return on Equity (ROE) of 88.10% and a Return on Assets (ROA) of 23.30%. The ROE is strong, indicating efficient use of shareholders' equity to generate profits. The ROA is healthy, suggesting management is effectively using company assets to generate earnings. The large gap between ROE and ROA suggests the company has significant leverage (debt), which amplifies returns but potentially increases risk.
Is NVO growing faster or slower than in previous periods?
Novo Nordisk's year-over-year quarterly revenue growth is 19.50%. This indicates positive revenue momentum, though at a moderate pace. Meanwhile, earnings growth is 15.00% year-over-year. Earnings are growing slower than revenue, which might indicate increasing costs or investments for future growth.
What does NVO's operating margin tell us about its business model?
Novo Nordisk's operating margin is 49.70%. This is an excellent operating margin that indicates the company has strong pricing power, efficient operations, or both. It suggests a robust business model with good cost control. Operating margins vary widely by industry, and in the pharmaceutical preparations sector, this margin should be evaluated relative to industry peers.

Dividend Information

Dividend Per Share

$11.40

Dividend Yield

2.26%

Ex-Dividend Date

3/31/2025

Dividend Date

4/8/2025

How does NVO's dividend yield compare to other investments?
Novo Nordisk's dividend yield is currently 2.26%. This yield is above the S&P 500 average (typically around 1.5-2%) and potentially competitive with some fixed-income investments, depending on current interest rates. In the pharmaceutical preparations industry, this yield should be evaluated against industry peers for a meaningful comparison.
What do the ex-dividend and dividend dates mean for NVO investors?
The next ex-dividend date for Novo Nordisk is 3/31/2025. This is the cut-off date for receiving the upcoming dividend. Investors who purchase shares before this date will receive the dividend, while those who buy on or after this date will not. The actual payment of this dividend will occur on 4/8/2025. The dividend amount is $11.40 per share.
How sustainable is NVO's dividend?
Novo Nordisk pays a dividend of $11.40 per share, with trailing twelve month earnings of $3.54 per share. This gives a dividend payout ratio of approximately 100.00%. This very high payout ratio could raise concerns about dividend sustainability if earnings decline in the future.

Company Size & Market

Market Cap

$307.42B

Shares Outstanding

3.37B

Book Value/Share

$31.21

Asset Type

Common Stock

What does NVO's market capitalization tell investors?
Novo Nordisk's market capitalization is $307.42B, which makes it a mega-cap company. Companies of this size are typically industry leaders with established global presence and significant market influence. Within the pharmaceutical preparations industry, this market cap places Novo Nordisk among the largest players in the sector.
What's the significance of NVO's book value per share?
Novo Nordisk's book value per share is $31.21, while its current market price is $79.92. This gives a price-to-book (P/B) ratio of 2.56. This P/B ratio is moderate and suggests investors are paying a reasonable premium above the company's accounting value, which may reflect expectations of future growth or profitability. In the pharmaceutical preparations industry, this P/B ratio should be compared to industry peers for context.
How does the number of outstanding shares affect NVO investors?
Novo Nordisk has 3.37B outstanding shares. The number of outstanding shares directly affects metrics like earnings per share (EPS) and can be influenced by corporate actions such as stock splits, buybacks, or new share issuances. With a market cap of $307.42B, each share represents ownership of approximately $91.26 of the company's total value. When companies reduce their outstanding shares through buyback programs, this can increase EPS and potentially support higher share prices, assuming other factors remain constant. Conversely, when new shares are issued, this can dilute existing shareholders' ownership stakes.

Analyst Ratings

Analyst Target Price

$91.11

14.00% upside potential

Analyst Recommendations

Strong Buy

2

Buy

4

Hold

4

Sell

1

Strong Sell

1

How should I interpret analysts' recommendations for NVO?
For Novo Nordisk, analysts have provided the following recommendations: 2 Strong Buy, 4 Buy, 4 Hold, 1 Sell, 1 Strong Sell. Analyst recommendations reflect professional opinions about a stock's potential performance, but they should be just one factor in your investment decisions. Each analyst may use different methodologies and timeframes for their assessments. Overall, analysts currently have a positive view on this stock.
What does the analyst target price mean for NVO?
The consensus analyst target price for Novo Nordisk is $91.11, compared to its current price of $79.92. This represents a potential upside of 14.00%. Analyst target prices typically reflect where professionals expect the stock price to be in 12 months. This consensus target is derived from individual price targets set by various analysts covering the stock, and it may be updated as market conditions change or as new information becomes available. Keep in mind that while target prices provide insight into professional expectations, they are not guarantees, and actual price performance can vary significantly from these targets.
How accurate are analyst forecasts for stocks like NVO?
Analyst forecasts, while informative, have inherent limitations in their accuracy. Studies have shown that analysts' predictions can be influenced by various biases, including optimism bias (tendency to be overly positive) and herding behavior (following other analysts' opinions). In the pharmaceutical preparations industry, forecasts may be particularly challenging due to factors like changing market conditions, competitive dynamics, regulatory changes, and macroeconomic shifts.
Historically, analysts have been more accurate when forecasting:
  • Stable, mature companies with predictable earnings
  • Near-term results rather than long-term performance
  • Companies with transparent business models
Consider analyst forecasts as one tool among many in your investment research, and evaluate them alongside other metrics, industry trends, and your own assessment of the company's fundamentals and market position.

Fundamentals last updated: Jun 2, 2025, 08:23 AM

Technical Indicators

RSI (14-day)

56.73

Neutral

50-Day Moving Average

$66.31

20.52% above MA-50

200-Day Moving Average

$93.79

-14.79% below MA-200

MACD Line

1.25

MACD Signal

0.64

MACD Histogram

0.60

Bullish

What does NVO's RSI value tell investors?
Novo Nordisk's current Relative Strength Index (RSI) is 56.73. This indicates neutral momentum as the RSI is in the middle range. Values around 50 suggest no clear directional bias. The RSI is a momentum oscillator that measures the speed and change of price movements on a scale from 0 to 100. It's used to identify overbought or oversold conditions and potential reversals.
How should I interpret NVO's moving averages?
Novo Nordisk's current price of $79.92 is above its 50-day moving average ($66.31) but below its 200-day moving average ($93.79). This may indicate a potential recovery or the beginning of a new uptrend, though the longer-term trend remains bearish. The 50-day moving average is below the 200-day moving average, forming what traders call a 'death cross,' which is generally considered a bearish signal. Moving averages smooth out price data to create a single flowing line, making it easier to identify the direction of the trend. The 50-day MA represents medium-term trend, while the 200-day MA reflects the long-term trend.
What is the MACD indicating about NVO's momentum?
For Novo Nordisk, the MACD Line is 1.25, the Signal Line is 0.64, and the MACD Histogram is 0.60. The positive MACD histogram indicates bullish momentum, with the MACD line above the signal line. This suggests buying pressure is currently stronger than selling pressure. The MACD (Moving Average Convergence Divergence) is a trend-following momentum indicator that shows the relationship between two moving averages of a security's price. The MACD line is calculated by subtracting the 26-period EMA from the 12-period EMA. The signal line is a 9-period EMA of the MACD line, and the histogram represents the difference between the MACD line and the signal line.

Indicators last updated: Jun 4, 2025, 07:27 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for NVO and get notified when the price changes.

Stay Ahead of the Market with Novo Nordisk Alerts

Set up price alerts for Novo Nordisk and get notified instantly when the price hits your target. Never miss an important price movement again.